Nina Shah

12.5k total citations · 1 hit paper
260 papers, 4.1k citations indexed

About

Nina Shah is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Nina Shah has authored 260 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Hematology, 140 papers in Oncology and 87 papers in Molecular Biology. Recurrent topics in Nina Shah's work include Multiple Myeloma Research and Treatments (139 papers), CAR-T cell therapy research (70 papers) and Protein Degradation and Inhibitors (38 papers). Nina Shah is often cited by papers focused on Multiple Myeloma Research and Treatments (139 papers), CAR-T cell therapy research (70 papers) and Protein Degradation and Inhibitors (38 papers). Nina Shah collaborates with scholars based in United States, Spain and United Kingdom. Nina Shah's co-authors include Saad Z. Usmani, Ajai Chari, Emma Scott, Khalid Mezzi, Muzaffar H. Qazilbash, Simrit Parmar, Uday Popat, Robert Z. Orlowski, Chitra Hosing and Richard E. Champlin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nina Shah

252 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

2020 304 citations Nina Shah, Ajai Chari et al. profile →

Peers

Countries citing papers authored by Nina Shah

Since Specialization

Citations

This map shows the geographic impact of Nina Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Shah more than expected).

Fields of papers citing papers by Nina Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Shah. The network helps show where Nina Shah may publish in the future.

Co-authorship network of co-authors of Nina Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Shah. A scholar is included among the top collaborators of Nina Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Shah. Nina Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy 2024 ·Blood Advances ·Guy Ledergor, (unknown), Kaichun Wu, Elizabeth McCarthy, Axel Hyrenius‐Wittsten, (unknown), (unknown), (unknown), Serena S. Kwek, Alexander Cheung, Sophia Bylsma, Erik Hansen, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Kole T. Roybal, Thomas Martin, Chun Ye, Lawrence Fong	19
2	Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Kavita Sharma, (unknown), (unknown), Nina Shah, Michael A. Bookman, Juraj Kavecansky, Fang Niu, Rita L. Hui	0
3	Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma 2024 ·Blood Advances ·Kevin Reyes, Yen‐Chun Liu, Chiung‐Yu Huang, Rahul Banerjee, T. John Martin, Sandy W. Wong, Jeffrey L. Wolf, Shagun Arora, Nina Shah, Ajai Chari, Alfred Chung	15
4	Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis 2023 ·Current Problems in Cancer ·Vanessa E. Kennedy, (unknown), (unknown), Nina Shah, Shagun Arora, Jeffrey L. Wolf, Thomas G. Martin, Mandar A. Aras, Alfred Chung, Sandy W. Wong	4
5	Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma 2023 ·Transplantation and Cellular Therapy ·Kevin Reyes, Chiung‐Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Rebecca L. Olin, Thomas Martin, Nina Shah, Rahul Banerjee	26
6	A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma 2022 ·Journal of Clinical Oncology ·Anita D’Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, (unknown), Kevin J. Freise, (unknown), Jeremy A. Ross, Akshanth R. Polepally, (unknown), Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar	84
7	Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy 2021 ·Blood Advances ·Swetha Kambhampati, Ying Sheng, Chiung‐Yu Huang, Sophia Bylsma, Mimi Lo, Vanessa E. Kennedy, (unknown), Thomas Martin, Jeffrey S. Wolf, Nina Shah, Sandy W. Wong	79
8	Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies 2021 ·Future Oncology ·Nina Shah, Miguel‐Angel Perales, Cameron J. Turtle, Mitchell S. Cairo, (unknown), Hayder Saeed, Lihua E. Budde, Alan Tan, Zachary Lee, Kazuharu Kai, (unknown), Jonathan Zalevsky, Mary Tagliaferri, Krina K. Patel	17
9	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma 2021 ·Blood ·Noopur Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina	66
10	Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy 2020 ·Blood ·Swetha Kambhampati, Bita Fakhri, Ying Sheng, Chiung‐Yu Huang, (unknown), (unknown), (unknown), Mimi Lo, Weiyun Z. Ai, Lawrence D. Kaplan, Thomas Martin, Jeffrey L. Wolf, Nina Shah, Charalambos Andreadis, Sandy W. Wong	10
11	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma 2020 ·Blood Advances ·Rafael Alonso, María‐Teresa Cedena, Sandy W. Wong, Nina Shah, Rafael Ríos, José M. Moraleda, Javier López‐Jiménez, Cristina Nevado García, (unknown), Antonio Valeri, Ricardo Sánchez, (unknown), Thomas G. Martin, Jeffrey L. Wolf, Juan José Lahuerta, Joaquín Martínez‐López	27
12	CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma 2020 ·Blood Advances ·(unknown), (unknown), Ruilin Tian, (unknown), (unknown), (unknown), Priya Choudhry, Torsten Hechler, Nina Shah, Sandy W. Wong, Thomas Martin, Jeffrey L. Wolf, Kole T. Roybal, Andreas Pahl, Jack Taunton, Arun P. Wiita, Martin Kampmann	37
13	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies 2019 ·Blood ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Leslie Popplewell, Charalambos Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Thomas G. Martin, Clifford DiLea, (unknown), Shannon Matheny, John P. Leonard, Arturo Molina	16
14	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), Paul Lin, Rima M. Saliba, Uday Popat, Qaiser Bashir, Nina Shah, Krina K. Patel, Simrit Parmar, Partow Kebriaei, Chitra Hosing, Stefan O. Ciurea, Börje S. Andersson, Elizabeth J. Shpall, Richard E. Champlin, Samer A. Srour, Muzaffar H. Qazilbash	10
15	Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients 2019 ·European Journal Of Haematology ·Kate Sully, Andrew Trigg, Nicola Bonner, (unknown), (unknown), Nina Shah, Emre Yücel, Sumeet Panjabi, Kim Cocks	30
16	Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) 2019 ·Blood ·Caitlin Costello, Tara Gregory, Syed Abbas Ali, Jesús G. Berdeja, Krina K. Patel, Nina Shah, Eric Ostertag, Chris Martin, Majid Ghoddusi, Devon J. Shedlock, Matthew A. Spear, Robert Z. Orlowski, Adam D. Cohen	43
17	Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy 2018 ·Blood ·Nina Shah, Melissa Alsina, David S. Siegel, Sundar Jagannath, Deepu Madduri, Jonathan L. Kaufman, Ashley Turka, (unknown), Monica Massaro, Kristen Hege, Fabio Petrocca, Jesús G. Berdeja, Noopur Raje	66
18	Ex Vivo Mesenchymal Precursor Cell–Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery 2017 ·Biology of Blood and Marrow Transplantation ·Rohtesh S. Mehta, Rima M. Saliba, Kai Cao, Indreshpal Kaur, Katy Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marín, Amin M. Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Richard E. Champlin, Marcos de Lima, Donna Skerrett, Elizabeth Burke, Elizabeth J. Shpall, Betül Oran	23
19	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee 2016 ·Biology of Blood and Marrow Transplantation ·Jeanne Palmer, Jeannine S. McCune, Miguel‐Angel Perales, David I. Marks, Joseph Bubalo, Mohamad Mohty, John R. Wingard, Angélo Paci, Moustapha Hassan, Christopher Bredeson, Joseph Pidala, Nina Shah, Paul Shaughnessy, Navneet S. Majhail, Jeff Schriber, Bipin N. Savani, Paul A. Carpenter	110
20	Late complications of mantle radiotherapy for Hodgkin's lymphoma 2000 ·UCL Discovery (University College London) ·Amen Sibtain, Aaron Bradshaw, Nina Shah, Peter Hoskin	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact